Placebo News and Research

RSS

Enzo Biochem fiscal 2010 total revenues increase 8% to $97.1 million

Enzo Biochem, Inc. today reported results for the fiscal fourth quarter, consistent with our announcement on September 20, 2010, and for the year ended July 31, 2010.

15 Oct 2010

FibroGen announces initiation of FG-3019 phase 2 study for reversing liver fibrosis

FibroGen, Inc. today announced initiation of a phase 2 study to compare the efficacy of FG-3019, a human monoclonal antibody against connective tissue growth factor (CTGF), with placebo in reversing liver fibrosis (scarring of the liver) due to chronic infection with hepatitis B virus (HBV).

15 Oct 2010

Bayhill to present BHT-3009 Phase 2 clinical trial data at European Committee Congress

Bayhill Therapeutics Inc, a clinical-stage biopharmaceutical company leveraging its proprietary BHT-DNA platform to develop targeted autoimmune disease treatments, today announced that it will present at the 26th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis and 15th Annual Conference of Rehabilitation in MS in Gothenburg, Sweden, data from its concluded Phase 2 clinical trial showing that baseline blood plasma anti-MBP (myelin basic protein) profiles identify responders to BHT-3009 treatment.

14 Oct 2010

Acceleron announces ACE-031 Phase 1b study results

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced preliminary results from a Phase 1b study to assess the safety, tolerability and pharmacodynamic (PD) activity of ACE-031 following multiple ascending doses in healthy postmenopausal volunteers.

14 Oct 2010

Antidepressant Reboxetine ineffective: Review

According to a new study, an antidepressant prescribed over the last 13 years is ineffective and potentially harmful. The drug in question is called Reboxetine and is available under the name of Edronax. The study showed that it works no better than a placebo.

13 Oct 2010

$1.5 million DOD award allows U-M scientists to pursue new application for nanoemulsion technology

The U.S. Department of Defense has awarded $1.5 million over three years to the Michigan Nanotechnology Institute for Medicine and Biological Sciences and to Ann Arbor-based NanoBio Corporation to develop and test nanoemulsions with potential to fight a wide range of wound infections, including drug-resistant forms.

13 Oct 2010

Buprenorphine implant decreases opioid usage in persons with opioid dependence

Helping to address the issue of medication adherence, persons with opioid dependence who had the medication buprenorphine implanted had less opioid use over 16 weeks, according to a study in the October 13 issue of JAMA.

13 Oct 2010

JAMA publishes Probuphine Phase 3 clinical trial data

Titan Pharmaceuticals, Inc. today announced that data from its previously completed and announced Phase 3 randomized, placebo-controlled clinical trial of Probuphine were published in the Journal of the American Medical Association (JAMA).

13 Oct 2010

Kennedy Krieger Institute launches phase II clinical trial to investigate Revatio for DMD treatment

Kennedy Krieger Institute announced today the launch of a first‐of‐its‐kind, phase II clinical trial to investigate a treatment for heart disease in individuals with Duchenne muscular dystrophy (DMD).

13 Oct 2010

MTN-007 phase trial evaluates vaginal microbicide to prevent rectal transmission of HIV

Tenofovir gel, a vaginal microbicide that has shown promise for preventing HIV through vaginal sex, is being tested in a new trial looking at its safety and acceptability when used rectally. The results of the study, being led by the U.S. National Institutes of Health (NIH)-funded Microbicide Trials Network (MTN), will help determine if the gel should be evaluated further for its potential to prevent HIV among both men and women who engage in receptive anal intercourse.

13 Oct 2010

Alkermes' VIVITROL medication for treatment of opioid dependence

Alkermes, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved VIVITROL(naltrexone for extended-release injectable suspension) for the prevention of relapse to opioid dependence, following opioid detoxification.

13 Oct 2010

FDA approves Vivitrol for treatment of opioid-dependent patients

The U.S. Food and Drug Administration today approved Vivitrol to treat and prevent relapse after patients with opioid dependence have undergone detoxification treatment.

13 Oct 2010

Smart for Life(R) to add Lepticore(R) to product line

Smart for Life(R), the trailblazing company featuring weight management products will begin adding Lepticore(R) to its product line this month.

12 Oct 2010

Abbott agrees to voluntarily withdraw obesity drug Meridia from U.S. market

Abbott Laboratories has agreed to voluntarily withdraw its obesity drug Meridia (sibutramine) from the U.S. market because of clinical trial data indicating an increased risk of heart attack and stroke, the U.S. Food and Drug Administration announced today.

12 Oct 2010

Albireo reports positive results from A3309 Phase IIb study in chronic idiopathic constipation

Albireo today announced positive top-line results from a Phase IIb study in chronic idiopathic constipation (CIC) assessing efficacy and safety of three different dose levels (5, 10 and 15 mg orally once a day) of the investigational drug A3309 during an eight week trial. Analyses of the data show clinically meaningful and statistically significant improvement for patients treated with A3309 compared to placebo-treated patients.

12 Oct 2010

Estrogen therapy may increase risk of kidney stones in postmenopausal women: Study

The use of estrogen therapy by postmenopausal women might increase the risk of developing kidney stones, according to findings by UT Southwestern Medical Center researchers.

12 Oct 2010

Folic acid supplement does not reduce cardiovascular events, cancer or death

Use of folic acid supplements appears to lower blood levels of the amino acid homocysteine—theorized to be a risk factor for heart and blood vessel disease—but does not appear to be associated with reduced rates of cardiovascular events, cancer or death over a five-year period, according to a meta-analysis of previously published studies in the October 11 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

12 Oct 2010

Estrogen therapy increases risk of kidney stone development in postmenopausal women

Use of estrogen therapy is associated with an increased risk of developing kidney stones in postmenopausal women, according to a report in the October 11 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

12 Oct 2010

$Balloon kyphoplasty relieves painful spine fractures in patients with metastatic cancer$

Balloon kyphoplasty relieves painful spine fractures in patients with metastatic cancer

A surgical technique appears to offer quick and effective relief for debilitating spinal fractures often suffered by patients with metastatic cancer, researchers reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan.

11 Oct 2010

New targeted therapy adds benefit to erlotinib in some patients with advanced lung cancer

A subset of lung cancer patients seem to live longer and experience delays in disease progression when a new drug that targets a cancer-associated molecule called MET is added to treatment with erlotinib, the results of a double-blind Phase-II trial show.

11 Oct 2010

Placebo News and Research

Enzo Biochem fiscal 2010 total revenues increase 8% to $97.1 million

FibroGen announces initiation of FG-3019 phase 2 study for reversing liver fibrosis

Bayhill to present BHT-3009 Phase 2 clinical trial data at European Committee Congress

Acceleron announces ACE-031 Phase 1b study results

Antidepressant Reboxetine ineffective: Review

$1.5 million DOD award allows U-M scientists to pursue new application for nanoemulsion technology

Buprenorphine implant decreases opioid usage in persons with opioid dependence

JAMA publishes Probuphine Phase 3 clinical trial data

Kennedy Krieger Institute launches phase II clinical trial to investigate Revatio for DMD treatment

MTN-007 phase trial evaluates vaginal microbicide to prevent rectal transmission of HIV

Alkermes' VIVITROL medication for treatment of opioid dependence

FDA approves Vivitrol for treatment of opioid-dependent patients

Smart for Life(R) to add Lepticore(R) to product line

Abbott agrees to voluntarily withdraw obesity drug Meridia from U.S. market

Albireo reports positive results from A3309 Phase IIb study in chronic idiopathic constipation

Estrogen therapy may increase risk of kidney stones in postmenopausal women: Study

Folic acid supplement does not reduce cardiovascular events, cancer or death

Estrogen therapy increases risk of kidney stone development in postmenopausal women

Balloon kyphoplasty relieves painful spine fractures in patients with metastatic cancer

New targeted therapy adds benefit to erlotinib in some patients with advanced lung cancer

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News